EDWIN CABAHUG: Open Payments
NPI 1972055952 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,041 in 20 payments from 11 companies in 2025. Trend: 2023 $225 · 2024 $481 · 2025 $1,041
Food & beverage: $1,041
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $151 |
| GlaxoSmithKline, LLC. | 4 | $149 |
| Gilead Sciences, Inc. | 1 | $140 |
| Lilly USA, LLC | 3 | $132 |
| Novo Nordisk Inc | 1 | $125 |
| Abbott Laboratories | 1 | $113 |
| E.R. Squibb & Sons, L.L.C. | 1 | $110 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $42 |
| Dexcom, Inc. | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $28 |
Products named: Epclusa, Ozempic, FREESTYLE LIBRE 3, Repatha, AREXVY, CAMZYOS, ZEPBOUND, JOURNAVX.
Industry payments across CA — which companies pay providers there.
